Saifuyuzu
4892.TPharmaceutical
Filed as Cyfuse Biomedical K.K. (2023-03–2026-08)
Financials · Standalone
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|---|
| Revenue | ¥231m | ¥54m | ¥61m | ¥374m | ¥708m | ¥137m |
| Operating income | −¥828m | −¥896m | −¥697m | −¥425m | ¥71m | — |
| Ordinary income | −¥761m | −¥870m | −¥586m | −¥433m | ¥145m | −¥327m |
| Total assets | ¥4.3bn | ¥3.5bn | ¥4.2bn | ¥4.8bn | ¥2.6bn | ¥2.2bn |
| Net assets / equity | ¥2.8bn | ¥2.5bn | ¥3.2bn | ¥3.8bn | ¥1.9bn | ¥1.5bn |
| Operating cash flow | −¥535m | −¥761m | −¥562m | −¥404m | ¥162m | −¥294m |
| EPS (basic) | ¥-86.78 | ¥-108.34 | ¥-75.42 | ¥-177.67 | ¥285.53 | ¥-658.34 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 11
| Period | Form | Figures |
|---|---|---|
| 2026-01-01 → 2026-06-30 | Half-year | 66 figures · EDINET |
| 2025-01-01 → 2025-12-31 | Annual | 109 figures · EDINET |
| 2025-01-01 → 2025-06-30 | Half-year | 66 figures · EDINET |
| 2024-01-01 → 2024-12-31 | Annual | 109 figures · EDINET |
| 2024-01-01 → 2024-06-30 | Half-year | 66 figures · EDINET |
| 2024-01-01 → 2024-03-31 | Quarterly Q1 | 42 figures · EDINET |
| 2023-01-01 → 2023-12-31 | Annual | 105 figures · EDINET |
| 2023-01-01 → 2023-09-30 | Quarterly Q3 | 44 figures · EDINET |
| 2023-01-01 → 2023-06-30 | Quarterly Q2 | 68 figures · EDINET |
| 2023-01-01 → 2023-03-31 | Quarterly Q1 | 29 figures · EDINET |
| 2022-01-01 → 2022-12-31 | Annual | 101 figures · EDINET |